Mission & Need

Develop materials that mitigate the foreign body response (FBR) to medical devices such as minimally invasive continuous glucose monitors (CGM), vascular access ports and shunts.

These devices trigger the FBR, which limits their functionality and longevity.

Our Solution

Controlled nitric oxide (NO) release from nanoparticles – these can be embedded within devices or deposited onto their surfaces within polymer films. NO is an endogenous, anti-inflammatory metabolite. The release of minute amounts of nitric oxide dramatically slows the FBR progression. This improves, for example, the accuracy and longevity of CGM devices and the function of other devices.

NO acts locally, so the deviceprotective effect is only delivered where it is needed.

The Initial Market

Diabetes affects more than 30 million Americans and more than 350 million people worldwide. CGMs improve blood glucose control and reduce the rate of diabetesassociated complications.

Roughly 25-30% of intensively managed patients now use the CGM systems sold by Dexcom (DXCM), Abbot (ABT) and Medtronic (MDT). This translates to a \$2.6B US market with an expected CAGR of 16% for the next few years. In addition to these three market leaders, there are many systems in development.

Our team represents decades of research, discovery, development and large-scale manufacturing experience from both medical technology and other high-tech industries.

- **Neal Hunter,** *Executive Chairman*. 30-year track record of innovative technology development & commercialization starting as a co-founder of Cree.
- Mark Tapsak, Ph.D., President. Medical device research scientist for over 25 years, holds 66 patents.
 Former Senior Scientist at Medtronic and Dexcom.
- Mark Schoenfisch, Ph.D., Chief Scientific Officer. Founding partner of KNOW Bio, LLC. Professor UNC with 20 years experience. 100+ articles on nitric oxide.

Seeking a Business Relationship

Intellectual Property
Out Licensing

M&A Transaction

Partnerships & Collaborations

